BCR signaling plays a central pathogenic role in CLL,17 with its importance underscored by current therapeutics such as Bruton tyrosine kinase inhibitors, which induce remission and improve patient survival.18 Here, BCR is linked to B-cell chronic lymphocytic leukemia.